A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes

Nauck, Michael A., Petrie, John R., Sesti, Giorgio, Mannucci, Edoardo, Courrèges, Jean-Pierre, Lindegaard, Marie L., Jensen, Christine B., Atkin, Stephen L.·2016·Diabetes Care
DOI 10.2337/dc15-0165

Cited by (233)

Items 201–233 of 233

  1. Semaglutide improves postprandial glucose and lipid metabolism and delays first-hour gastric emptying in subjects with obesity
    John Edward Blundell, Mads Buhl Axelsen, Ashley Brooks, Anne Flint, Trine Kvist, Eirik Quamme Bergan, Julie Hjerpsted · 2016 · Diabetes Research and Clinical Practice
  2. Semaglutid – ein neuer langwirksamer GLP-1-Rezeptor-Agonist mit nachgewiesener kardiovaskulärer Ereignisreduktion bei Typ-2-Diabetes
    Jochen Seufert, Michael Albrecht Nauck, Baptist Gallwitz · 2017 · Diabetologie und Stoffwechsel
  3. Semaglutid – ein neuer langwirksamer GLP-1-Rezeptor-Agonist mit nachgewiesener kardiovaskulärer Ereignisreduktion bei Typ-2-Diabetes
    Jochen Seufert, Michael Albrecht Nauck, Baptist Gallwitz · 2018 · Diabetes aktuell
  4. Response to “Liraglutide Effectiveness: Is There a Real‐World Clinical Benefit?”
    Sean Wharton, Aiden Liu, Arash Pakseresht, Emil Nørtoft, Christiane Lundegaard Haase, Johanna Mancini, G. Sarah Power, Sarah VanderLelie, Rebecca A. G. Christensen · 2019 · Obesity
  5. Progress toward a monolithically integrated coherent diode laser array. Interim report
    Gary A. Evans, E. Garmire, H. M. Stoll, Judith A. Osmer, William E Soady · 1981 · OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information)
  6. Impact of Cotadutide Drug on Obese Individuals with Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis
    Mahmoud Ali, Ahmed Hafez Allam, Mahmoud Shaaban Abdelgalil, Mohammed Tarek Hasan, Mohammed Magdy El-Ghannam, Osama M Ghogar, Asmaa Ahmed Elrashedy, Mohamed Abd‐ElGawad · 2022 · Research Square
  7. Semaglutide as an Antidiabetic Medication: A Summary of the Evidence from the Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes Clinical Trial Program
    Gurdeep Singh, Matthew Krauthamer, Meghan Bjalme-Evans · 2021 · International Journal of Diabetes and Endocrinology
  8. Semaglutide (Wegovy)
    CADTH · 2022 · Canadian Journal of Health Technologies
  9. AN INSIGHT INTO THE TREATMENT STRATEGIES OF OBESITY USING SEMAGLUTIDE AND ITS COMPETITIVE ANALOGUES: A REVIEW ARTICLE
    Nahid Rao, Reenoo Jauhari, Vaishali Sati, Pallavi Godiyal · 2022 · Journal of Applied Pharmaceutical Sciences and Research
  10. Efficacy and safety of Xiang-Sha-Liu-Jun-Zi (XSLJZ) for treatment of Semaglutide-induced gastrointestinal side effects: Study protocol for a multicentre, randomized, open-label trial
    Meixi Liu, Xianliang Qiu, Shunlian Fu, Yuting Tian, Li Wen, Qing Li, Qiu Chen · 2023 · Medicine Case Reports and Study Protocols
  11. Investigating Semaglutide in Adult Patients on Body Weight Compared with Other GLP-1 Drugs
    Shroug Farrash, Lujain Aleisa, Nardeen Z. Alhazmi, Nouf Almatrafi, Taef Alharbi, Shahad Kelantan, Lina Alotaibi, Wed Hunaydi, Sara Alnimari, Noor Alqarni et al. · 2023 · International Journal Of Pharmaceutical Research And Allied Sciences
  12. Exenatide administration time determines the effects on blood pressure dipping in db/db mice via modulation of food intake and sympathetic activity
    Aaron N. Chacon, Wen Su, Tianfei Hou, Zhenheng Guo, Ming Cui Gong · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
  13. Fecal microbiome predicts treatment response after the initiation of semaglutide or empagliflozin uptake
    Annabel Klemets, Ingrid Reppo, Kertu Liis Krigul, Vallo Volke, Oliver Aasmets, Elin Org · 2024 · medRxiv
  14. Efficacy of GLP-1 receptor agonists on weight loss, body mass index and waist circumference for obese or overweight patients: A systematic review, meta-analysis and meta-regression of 47 randomized-controlled trials
    Hon Jen Wong, Bryan Sim, Yao Hao Teo, Yao Neng Teo, Mark Y. Chan, Leonard L.L. Yeo, Pei Chia Eng, Benjamin Yong‐Qiang Tan, Naveed A. Sattar, Mayank Dalakoti et al. · 2025
  15. An updated patent review of small molecule glucagon receptor antagonists (2020–2024)
    Chunyang Wang, Liyang Lyu, Dongyang Liu, Hu Yuanjia · 2025 · Expert Opinion on Therapeutic Patents
  16. Impact of Glucagon-Like Peptide-1 Receptor Agonists on Hip Arthroplasty Outcomes: A Systematic Review and Meta-Analysis
    H. Zaffar, M. Imran, Sulaiman Hussain, Farwah Rushd · 2025 · Cureus
  17. The Role of Adaptive and Innovative Trial Designs in Diabetes Research: A Scoping Review
    Ashni Goshrani, Rose Lin, Leonid P. Churilov, Michele Gaca, Christine A. SOMERVILLE, Andrew A. Farmer, Kamlesh Khunti, Elizabeth Holmes‐Truscott, Negar Naderpoor, David Norman O'Neal et al. · 2025 · Diabetes Care
  18. Impact of Glucagon-Like Peptide-1 Receptor Agonists on Knee Arthroplasty Outcomes
    Haroon Zaffar, Muhammad Imran, Farwah Rushd · 2025 · Indian Journal of Orthopaedics
  19. Additional file 1 of Efficacy and tolerability of the Subcutaneous Semaglutide for type 2 Diabetes patients: an updated systematic review and meta-analysis
    Hu, Shanshan, Su, Xiaorong, Fan, Guorong · 2023 · Figshare
  20. Implication des récepteurs nucléaires HNF-4α et HNF-4γ dans la fonction entéroendocrine et la susceptibilité à l'obésité et au diabète de type II
    Sami Ayari · 2017 · theses.fr (ABES)
  21. Impact of incretin therapies on biochemical and imaging outcomes in metabolic dysfunction–associated steatotic liver disease
    Nicole Ann Tesoro, Frederick Berro Rivera, Nathan Ross B. Bantayan, John Vincent Magalong, Romaine Tomada, Maria Antonia Wong, Gabriel A Tangco, Polyn Luz S Pine, Jasvin Kurundrayil Manha, Elora Shyama Tanni et al. · 2026 · American Journal of Preventive Cardiology
  22. Risk Factors for Hypoglycemia in Type 2 Diabetes Mellitus Patients Using Once-Weekly Semaglutide: A Matched Case-Control Study
    P. Amirthalingam, Fawaz Alarawi, Loay Mohammed Jassas Alagwar, Mohammed Alatawi, Mohanad Saleh Saeed Alfahmi Alzahrani, A. Albalwi, Ahmed Al-Rashidi, Ahmed Mohsen Elsaid Hamdan, Saleh Fahad Alqifari, Hanan M. Alshareef et al. · 2026 · Therapeutics and Clinical Risk Management
  23. The systems medicine view of semaglutide: from clinical trials to molecular mechanisms
    Rui Miguel Pinheiro Vitorino · 2026 · Expert Review of Clinical Pharmacology
  24. Current diabetes drugs: Lessons learned and implications for next-generation therapeutics
    Jiayu Liao, Zhaotong Cong, Ke Liu, Hanyun Que, Fang Liu · 2026 · The Innovation Drug Discovery
  25. New horizons in Type 2 diabetes mellitus treatment and prognosis management with glucagon-like peptide-1 receptor agonists
    Elena Valer'evna Biryukova, Шинкин Михаил Викторович · 2026 · Meditsinskiy sovet = Medical Council
  26. Oral nonpeptide GLP-1 receptor agonist VCT220 for obesity treatment: a randomized, double-blind, phase II trial
    Linong Ji, Leili Gao, Ben Li, Mei Liu, Xianghua Zhang, Chao Meng · 2026 · Signal Transduction and Targeted Therapy
  27. Higher semaglutide dose is associated with lower neuropsychiatric event incidence independent of weight loss
    Karthik Murugadoss, AJ Venkatakrishnan, Venky Soundararajan · 2026 · npj Metabolic Health and Disease
  28. Liraglutide
    Qing Zhong, Ashley L. Yang, Ines N Volic · 2026 · Elsevier eBooks
  29. Considerations and challenges in microdosing of GLP-1-based receptor agonists
    Haley Beck, Jennifer Nicole Clements · 2026 · Expert Opinion on Pharmacotherapy
  30. Glucose-Lowering Therapies in Type 2 Diabetes-Associated Sarcopenia: Mechanisms, Clinical Evidence and a Muscle-Centred Framework
    Jing Zhang, Xiaodan Zhai, Sha Sha, Li Zhang · 2026 · Drugs
  31. Real‐World Semaglutide Initiation Behaviours in the United States: Impact on Early Treatment Discontinuation and on 1‐Year Persistence
    Ligia Maria Belalcazar, Daoqi Gao, Saman Modi, Aima Meer, Yong‐Fang Kuo · 2026 · Diabetes Obesity and Metabolism
  32. Pharmacological Mechanisms of Once-Weekly GLP-1 Receptor Agonists for Type 2 Diabetes Management
    Md Afaque Ali, Sani Das, Rajiv Ranjan Kumar, Kumar Rabindra · 2026 · International Journal of Innovative Science and Research Technology (IJISRT)
  33. Simulation of Gastrointestinal Adverse Events with Tolerance Development during GLP-1 Receptor Agonist Treatment
    Mathilde Guldbæk Arentsen, Selma El Messaoudi, Ali Mohebbi, Henrik L. Bengtsson, Thomas Sparre, John Bagterp Jørgensen · 2026 · IFAC-PapersOnLine